Britain and America have signed a major commercial pact that will maintain zero import taxes on UK medicine shipments entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This move secures that duties on these key products will stay at zero for a period of the next three years.
This agreement comes after previous statements to significantly raise import taxes on branded drug products, with figures mentioned as high as 100%.
"This deal with the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British drug exports," a statement declared.
Commercial Impact
Medicines are one of the the United Kingdom's largest goods shipped to the United States, which is easily the primary destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount accounted for a significant portion of all goods exports in that timeframe.
"This agreement protects jobs, increases capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several notable pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, refunds exceeded 20%.
Broader Context
This agreement comes amid a long-running row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were intensified by arguments that American patients were charged several times more for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
